SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

导出 OA

翻译打印收藏纠错

作者： Prithviraj,Bose ^[1] ; Srdan,Verstovsek ^[2]

作者单位： Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: pbose@mdanderson.org. ^[1] Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. ^[2]

关键词 Disease progression Fedratinib Imetelstat JAK inhibitors KRT-232 Luspatercept Momelotinib Pacritinib Pelabresib Ruxolitinib failure

主题词动物(Animals);考来烯胺树脂(Cholestyramine Resin);疾病恶化(Disease Progression);人类(Humans);小鼠(Mice);原发性骨髓纤维化(Primary Myelofibrosis);蛋白激酶抑制剂(Protein Kinase Inhibitors)

DOI 10.1016/j.clml.2021.06.008

PMID 34272171

发布时间 2023-09-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Clinical lymphoma, myeloma & leukemia

2021年21卷10期

641-649页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

检索历史清除